To date, Madam Therapeutics and her academic partners have raised over 9 million Euro’s ‘non-dilutive funding’ (subsidies and investments by the founders) for the development of our platform of patented SAAP based products, with successful in-vitro results.
In August 2018, Madam Therapeutics closed a seed funding round of 1,1M Euros. The investment came from a network of European business angels.
Madam Therapeutics is currently actively seeking additional funding into the company. For info or to get a copy of our investment information package, contact:
Remko van Leeuwen
+31 71 2040 105 Extension 100